Supporting Somavert patients
Advice and support services to help you and your patients optimise your experience with Somavert.
Click here for Somavert (pegvisomant) Prescribing Information.
Somavert has a positive dose response, and dosing should be titrated to optimise IGF-I normalisation and improve symptoms1,2
Help find their personal optimum |
![]() |
The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response*1 |
Simplified proportion of patients achieving IGF-I control on each dose shown for illustrative purposes. *Maximum recommended dose of Somavert shold not exceed 30 mg/daily.
Discover how patients can incorporate daily self-administration into their routine |
A Somavert patient demonstrates how the pre-filled diluent syringe enables straightforward reconstitution and administration at home |
References
- Somavert Summary of Product Characteristics. December 2020. Available at https://www.medicines.org.uk/emc/medicine/14353
- Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.
PP-SOM-GBR-0766. December 2020.
Starter kit contents are designed to help your patients feel confident with Somavert and self-administration
Each Somavert starter kit contains:
Patient information booklets |
|
Reconstitution guides |
|
Practising tools |
|
Day-to-day injecting and ongoing support |
*Items are subject to change. |
PP-SOM-GBR-0766. December 2020.
We offer a range of services that help your patients at home with medication delivery and face-to-face support
Somavert delivery every four weeks ![]() |
Standard homecare service: up to two home nurse visits ![]() |
Specialist homecare service: AcroCare ![]() |
Watch our guides on starting new patients according to each type of service
The patient journey with AcroCare |
This animation explains how to start new Somavert patients using the AcroCare service |
The patient journey with a standard homecare service |
This animation explains how to start new Somavert patients using a standard homecare service |
How AcroCare works
Specialist nurse support from day one |
![]() |
Home visits to help patients feel confident with Somavert |
|
Named nurse phone calls to help keep them on track* |
|
*Call volumes may vary by area and need.
PP-SOM-GBR-0766. December 2020.
Somavert has a positive dose response, allowing flexible dose titration to achieve IGF-I normalisation and improve symptoms1,2
IGF-I normalisation rates with increasing dose strengths |
![]() |
Percentage of Somavert patients achieving IGF-I normalisation after 12 weeks of treatment2 |
*p=0.02. **p<0.001.
Somavert is a daily subcutaneous injection available in five vial sizes of 10 mg, 15 mg, 20 mg, 25 mg and 30 mg
The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response1
|
†Please refer to the Summary of Product Characteristics for the full information about storage.
References
- Somavert Summary of Product Characteristics. December 2020. Available at: https://www.medicines.org.uk/emc/product/64/smpc
- Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.
PP-SOM-GBR-0766. December 2020.
Patients receiving homecare services will have their own dedicated, nurse-led helpline to support with patient enquiries
All patients with either standard or the enhanced AcroCare homecare services will be given their own dedicated helpline number to call
A freephone Pfizer Endocrine Helpline service is also available to clinicians and patients on 0800 521249
Email: [email protected]
Opening hours
Monday - Thursday: 9am - 5pm
Friday only: 9am - 4pm
(Answer phone available out of hours)
The Pfizer Endocrine Helpline team of nurses provides direct support for patients not receiving homecare services
We typically handle any queries relating to medication and supplies deliveries, reconstitution and self-administration advice.
PP-SOM-GBR-0766. December 2020.